S.T. Stent Overview
S.T. Stent develops a composite, removable sinus stent designed to be placed in the ethmoid sinus following functional endoscopic sinus surgery to keep the cavity open for up to 28 days. The stent improves patient outcomes and reduces the probability of revision surgeries. The S.T. Stent adapts to the patients anatomy and does not irritate the tissue or migrate. It provides strong, stable support for the sinus walls and is made from biocompatible materials. The stent can be easily removed at any time in a minimally invasive procedure performed in the doctors office without the need for anesthesia. In 2018 the company was awarded FDA clearance for its sinus stent. S.T. Stent is part of the Trendlines Medical portfolio.
Cumulative Funding Raised Over Time ($)
$450KApr 2015
$450KJul 2024
$1.7MNov 2022
Latest News
growth-positive
New revolutionary device can improve outcome of sinus surgery
StStent, a medical device company, has developed a product called ArchSinus that can improve the healing process for patients suffering from chronic sinusitis who undergo functional endoscopic sinus surgery (FESS). The device has undergone successful clinical trials in Israel and the US, and the company expects to have several customers for the product by the end of the year. StStents latest funding round, launched using ExitValleys platform, has already reached 40% of its goal.
CustomersInvestment
growth-positive
S.T.Stent Keeps Sinus Cavity Supported Post Surgery for Nearly a Month
STS Medical, an Israeli company, has received FDA clearance for its S.T.Stent sinus stent. The device is used for the treatment of chronic sinusitis and other related conditions. It is flexible, conforms to the sinus cavity, and is designed to anchor in place. The device is made of biocompatible materials and can be left in the patients sinus cavity for up to four weeks. Removal is a simple in-office procedure. This FDA clearance is expected to have a positive impact on the growth of STS Medical.
Customers
growth-positive
Israeli startup gets FDA nod for stent to help sinusitis sufferers
The US Food and Drug Administration has approved a nasal implant developed by Israeli startup STS Medical Ltd. The implant is designed to reduce the need for operations for individuals with chronic sinusitis. The self-expanding tube, made of nitinol, prevents post-surgical complications such as inflammation and scarring. The company predicts that the implant will reduce the probability of additional surgical procedures by 50%. The implant is expected to be available in Israel within six months and in the US by the end of the year. Entellus Medical Inc., a US-based medical technology firm, has expressed interest in the product.
Customers
growth-positive
STS Medical Receives FDA Regulatory Clearance
STS Medical Ltd., a portfolio company of The Trendlines Group Ltd., has received regulatory clearance from the FDA for its composite sinus stent. The stent, developed by S.T.Stent, is designed to keep the sinus cavity open after Functional Endoscopic Sinus Surgery (FESS) to reduce the need for revision surgeries. The FDA clearance allows the company to market the product in the U.S. The company is well-positioned for commercialization and has received interest from potential partners and distributors. The stent can also be used for other conditions such as chronic allergic rhinitis. The article was published on January 8, 2018.
CustomersPartners
growth-positive
S.T. Stent Completes $450k Raise
S.T. Stent, a portfolio company of Trendlines Medical, has raised $450k in funding. They have developed a removable nasal stent for implantation following sinus surgery, which helps reduce the need for revision surgery. The funds raised will enable them to gain regulatory approval for their device.
Investment
| Sector | Health Tech & Life Sciences |
Funding
| Total funding | $1.76M |
| Last funding | Undisclosed |
| Stage | Seed |
| Rounds | 4 |
| Investors | 4 |
Team Members
1
Employees: 1-10
Web & Social Links
| Website | ststent.com |
Locations
Misgav, Israel
Photos & Videos
3 item(s)
S.T. Stent Business
Business models
B2B
Product stage
Released
Employees
1-10
Sector
Health Tech & Life SciencesMedical DevicesMedical Treatment & TherapeuticsTarget Customer
Healthcare & Life SciencesHealthcareProvidersCore Technology
Materials & SubstancesImplantsTags (11)
medical-devicesinfectionsurgeryminimally-invasivestentallergychronic-diseaserespiratorymedical-productsdoctorshealthcare-providersGeographic Markets
GlobalS.T. Stent Financials
$1.76M
Total funding
Undisclosed
Capital raised
Undisclosed
Last funding
Seed
Funding stage
4
Total rounds
4
Investors
Cumulative Funding Raised Over Time ($)
$450KApr 2015
$450KJul 2024
$1.7MNov 2022
Private Equity Funding
Undisclosed Round
Jul 2024
Undisclosed
Katao Venture Partners (Lead)
Equity crowdfunding
Nov 2022
$1.25M
ExitValley, The Trendlines Group
Seed
Apr 2015
$450K
Undisclosed Investor(s), The Trendlines Group
Non-Equity Funding
GrantEvent
Aug 2018
$61K
EU Horizon 2020
S.T. Stent Lifecycle
Cumulative Funding Raised Over Time
$450KApr 2015
$450KJul 2024
$1.7MNov 2022
All Events
Undisclosed Round
Jul 2024
Undisclosed
Katao Venture Partners (Lead)
Equity crowdfunding
Nov 2022
$1.25M
ExitValley, The Trendlines Group
Seed
Apr 2015
$450K
Undisclosed Investor(s), The Trendlines Group
GrantEvent
Aug 2018
$61K
EU Horizon 2020
S.T. Stent News
5 articles
growth-positive
New revolutionary device can improve outcome of sinus surgery
StStent, a medical device company, has developed a product called ArchSinus that can improve the healing process for patients suffering from chronic sinusitis who undergo functional endoscopic sinus surgery (FESS). The device has undergone successful clinical trials in Israel and the US, and the company expects to have several customers for the product by the end of the year. StStents latest funding round, launched using ExitValleys platform, has already reached 40% of its goal.
CustomersInvestment
growth-positive
S.T.Stent Keeps Sinus Cavity Supported Post Surgery for Nearly a Month
STS Medical, an Israeli company, has received FDA clearance for its S.T.Stent sinus stent. The device is used for the treatment of chronic sinusitis and other related conditions. It is flexible, conforms to the sinus cavity, and is designed to anchor in place. The device is made of biocompatible materials and can be left in the patients sinus cavity for up to four weeks. Removal is a simple in-office procedure. This FDA clearance is expected to have a positive impact on the growth of STS Medical.
Customers
growth-positive
Israeli startup gets FDA nod for stent to help sinusitis sufferers
The US Food and Drug Administration has approved a nasal implant developed by Israeli startup STS Medical Ltd. The implant is designed to reduce the need for operations for individuals with chronic sinusitis. The self-expanding tube, made of nitinol, prevents post-surgical complications such as inflammation and scarring. The company predicts that the implant will reduce the probability of additional surgical procedures by 50%. The implant is expected to be available in Israel within six months and in the US by the end of the year. Entellus Medical Inc., a US-based medical technology firm, has expressed interest in the product.
Customers
growth-positive
STS Medical Receives FDA Regulatory Clearance
STS Medical Ltd., a portfolio company of The Trendlines Group Ltd., has received regulatory clearance from the FDA for its composite sinus stent. The stent, developed by S.T.Stent, is designed to keep the sinus cavity open after Functional Endoscopic Sinus Surgery (FESS) to reduce the need for revision surgeries. The FDA clearance allows the company to market the product in the U.S. The company is well-positioned for commercialization and has received interest from potential partners and distributors. The stent can also be used for other conditions such as chronic allergic rhinitis. The article was published on January 8, 2018.
CustomersPartners
growth-positive
S.T. Stent Completes $450k Raise
S.T. Stent, a portfolio company of Trendlines Medical, has raised $450k in funding. They have developed a removable nasal stent for implantation following sinus surgery, which helps reduce the need for revision surgery. The funds raised will enable them to gain regulatory approval for their device.
Investment
S.T. Stent Team
Employee Info
| Employees (range) | 1-10 |
| Exact count | 2 |
| Team members | 1 |
Similar Companies
Similar companies data is computed dynamically and not stored in the entity profile. This section requires implementing a similarity query (e.g. by classification overlap, sector, district).
This entity has 8 classification IDs that could be used for matching.
S.T. Stent Internal
Recent Updates
No update log entries.
Note: Free-text notes visible in the original Finder "Internal" tab are not present in the imported profile data. Only the update audit log is available.
Admin Info
| Confidence | 90/100 |
| Missing | markets, not claimed |
| BI Verification | Sharon Shapira |
| Registrar ID | 514987965 |
| Crunchbase | s-t-stent |
| Creator | Rebecca Mack |
| Creator email | rebeccamack26@gmail.com |
| Last updater | Matan Eblagon |
| Updater email | matane@sncentral.org |
| Last update | 2024-09-25T00:00:00.000Z |
| Created | 2014-07-31T00:00:00.000Z |